Sunday, June 18, 2017 9:25:08 PM
https://www.dropbox.com/s/myt5h9oj0fjgzt5/Summary%20Judgment%20motions%20denied%202017-1.pdf?dl=0
The memo is a good refresher on the long and tortuous history of this litigation.
Amphastar sought summary judgment on the grounds of invalidity and non-infringement, whereas Momenta sought summary judgment dismissing Amphastar's equitable defenses (as well as a separate trial) relating to Momenta's behavior surrounding the circumstances under which Momenta's patented test came to be listed in the United States Pharmacopeia (“USP"), e.g., Momenta and it's employee Dr. Shriver failed to disclose Momenta's pending patent application for the test.
I have to say that reading the description of the equitable defense, Momenta's behavior seems a bit dicey.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM